Cancer centers in the U.S. are still facing drug shortages, with 89% reporting deficits in crucial medications, though improvements have been seen in shortages of carboplatin and cisplatin. The shortages extend to various anti-cancer agents and supportive care drugs, impacting clinical trials and patient care. Despite efforts to address shortages, challenges persist in drug supplies, affecting chemotherapy regimens. These shortages have been ongoing despite some alleviation in shortages of specific drugs like vinblastine, etoposide, and topotecan. The root causes of drug shortages, including manufacturing issues and lack of resilience in the supply chain, continue to pose challenges for cancer centers and patients.